It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Rising Biosciences, Inc. (“RBII”) (CUSIP No. 76761W108) because of questions regarding the accuracy and adequacy of information in the marketplace about the company and its securities since at least April 16, 2020. Those questions relate, in part, to statements in April 16, 2020 and July 17, 2020 press releases in which RBII suggested that some of the products it claims to have launched in response to COVID-19, including Oxithymol, the Oxi Thyme system, and/or their ingredients, are approved by the CDC or registered with the EPA.

RBII is a Delaware corporation with its principal place of business located in Sandusky, Ohio. RBII’s common stock is quoted and traded on OTC Link (previously “Pink Sheets”), whose parent company is OTC Markets Group Inc., under the symbol RBII. As of August 10, 2020, RBII had seven market makers, and was eligible for the “piggyback” exception of Rule 15c2-11(f)(3) under the Securities Exchange Act of 1934.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT on August 25, 2020, through 11:59 p.m. EDT on September 8, 2020.

By the Commission.

Vanessa A. Countryman
Secretary